Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2013 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all The following term was not found in PubMed: psuedokinase-domain
Page 1
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.
Toms AV, Deshpande A, McNally R, Jeong Y, Rogers JM, Kim CU, Gruner SM, Ficarro SB, Marto JA, Sattler M, Griffin JD, Eck MJ. Toms AV, et al. Nat Struct Mol Biol. 2013 Oct;20(10):1221-3. doi: 10.1038/nsmb.2673. Epub 2013 Sep 8. Nat Struct Mol Biol. 2013. PMID: 24013208 Free PMC article.
The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and the equivalent mutation in Jak1 (V658F) is found in T-cell leukemias. Crystal structures of wild-type and V658F-mutant human Jak1 pseudokinase reveal a conformational switch …
The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and the equivalent mutation in Jak1 (V658F) is found …
In vivo selection of genetically modified erythroid cells using a jak2-based cell growth switch.
Zhao S, Weinreich MA, Ihara K, Richard RE, Blau CA. Zhao S, et al. Mol Ther. 2004 Sep;10(3):456-68. doi: 10.1016/j.ymthe.2004.05.014. Mol Ther. 2004. PMID: 15336646 Free article.
Cell-based therapies have potential widespread applications in clinical medicine, and methods for controlling the fate of transplanted cells are needed. We have previously described a means for directing the growth of genetically modified cells in vivo using a derivative o …
Cell-based therapies have potential widespread applications in clinical medicine, and methods for controlling the fate of transplante …